| pubmed-article:1817778 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1817778 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:1817778 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1817778 | lifeskim:mentions | umls-concept:C0003811 | lld:lifeskim |
| pubmed-article:1817778 | lifeskim:mentions | umls-concept:C0810633 | lld:lifeskim |
| pubmed-article:1817778 | pubmed:issue | 8 Suppl | lld:pubmed |
| pubmed-article:1817778 | pubmed:dateCreated | 1992-7-14 | lld:pubmed |
| pubmed-article:1817778 | pubmed:abstractText | The use of an antitachycardia pacemaker in the treatment of hyperkinetic supraventricular arrhythmias is founded on a reliable electrophysiological ground and on an high technology. Nevertheless the clinical impact of this approach is not considerable since the 5% to 7% of the potential candidates are in effect treated with an antitachycardia device. The success of new therapeutical procedures (i.e. catheter ablation) together with the shifting of the clinical, technical and commercial interest towards the electrical treatment of the malignant ventricular tachyarrhythmias are the main causes of the minor role that now the antitachycardia pacemakers play in the management of the patients with hyperkinetic supraventricular arrhythmias. | lld:pubmed |
| pubmed-article:1817778 | pubmed:language | ita | lld:pubmed |
| pubmed-article:1817778 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1817778 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1817778 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1817778 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1817778 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:1817778 | pubmed:issn | 0393-1978 | lld:pubmed |
| pubmed-article:1817778 | pubmed:author | pubmed-author:FurlanelloFF | lld:pubmed |
| pubmed-article:1817778 | pubmed:author | pubmed-author:VergaraGG | lld:pubmed |
| pubmed-article:1817778 | pubmed:author | pubmed-author:GuarnerioMM | lld:pubmed |
| pubmed-article:1817778 | pubmed:author | pubmed-author:InamaGG | lld:pubmed |
| pubmed-article:1817778 | pubmed:author | pubmed-author:GramegnaLL | lld:pubmed |
| pubmed-article:1817778 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1817778 | pubmed:volume | 36 | lld:pubmed |
| pubmed-article:1817778 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1817778 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1817778 | pubmed:pagination | 99-103 | lld:pubmed |
| pubmed-article:1817778 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1817778 | pubmed:meshHeading | pubmed-meshheading:1817778-... | lld:pubmed |
| pubmed-article:1817778 | pubmed:meshHeading | pubmed-meshheading:1817778-... | lld:pubmed |
| pubmed-article:1817778 | pubmed:meshHeading | pubmed-meshheading:1817778-... | lld:pubmed |
| pubmed-article:1817778 | pubmed:meshHeading | pubmed-meshheading:1817778-... | lld:pubmed |
| pubmed-article:1817778 | pubmed:meshHeading | pubmed-meshheading:1817778-... | lld:pubmed |
| pubmed-article:1817778 | pubmed:meshHeading | pubmed-meshheading:1817778-... | lld:pubmed |
| pubmed-article:1817778 | pubmed:meshHeading | pubmed-meshheading:1817778-... | lld:pubmed |
| pubmed-article:1817778 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1817778 | pubmed:articleTitle | [Role of antitachycardia pacemakers in the treatment of supraventricular hyperkinetic arrhythmias]. | lld:pubmed |
| pubmed-article:1817778 | pubmed:affiliation | Divisione di Cardiologia e Centro Aritmologico, Ospedale S Chiara, Trento. | lld:pubmed |
| pubmed-article:1817778 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1817778 | pubmed:publicationType | English Abstract | lld:pubmed |
